Gilead Sciences initiates two phase 3 studies of investigational antiviral remdesivir for treatment of COVID-19

Remdesivir is an investigational nucleotide analogue with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens including Ebola, Marburg, MERS and SARS. It is not yet licensed or approved anywhere globally


Biospace Inc.